Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

NuVasive Announces Christopher Barry to Succeed Gregory Lucier as CEO

NuVasive (NUVA) named J. Christopher Barry to succeed Gregory T. Lucier as Chief Executive Officer, effective November 5. He will also join NUVA's Board of Directors, for which Mr. Lucier will continue to serve as Chairman.

Mr. Barry joins NUVA from Medtronic, where he has served as Senior Vice President and President, Surgical Innovations, since January 2015. The business unit, part of Medtronic's Minimally Invasive Therapies Group, focuses on obesity and diseases of the gastrointestinal tract, lung, abdominal wall, pelvic region, head and neck. He also led development of Medtronic's general surgical robotics initiative. (This does not include spine-related robotics.)

Mr. Lucier joined NUVA's board in December 2013, and assumed the CEO role in mid-2015. Within this timeframe, as noted by Wells Fargo analysts, the company has shifted from implant-focused to systems-based implant-directed with the announcement of Pulse™ surgical automation, the foundation for the company's Surgical Intelligence™ system, and made transitions in manufacturing at the West Carrollton, Ohio facility. NuVasive broke past $1 billion in revenue in 2017.

The company has also announced the promotion of Matt Link, present Executive Vice President of Strategy, Technology and Corporate Development, to the role of President. Mr. Link began with NUVA in 2006 as a regional business manager and was elevated through varying roles that included build-up of the U.S. Commercial organization. He accepted his current role in 2017. Prior to his time with NUVA, Mr. Link held sales representative positions in spine and orthopaedics for DePuy Synthes.

Earlier in October, Skip Kiil, formerly Executive Vice President, Global Commercial for NUVA, tendered his resignation effective at month-end. He is pursuing another opportunity outside of the spine industry.

Sources: NuVasive, Inc.; Form 8-K,; Wells Fargo Securities, LLC

Julie Vetalice is ORTHOWORLD’s Editorial Assistant. She can be reached by